-
公开(公告)号:EP0547530B1
公开(公告)日:1996-09-11
申请号:EP92121203.1
申请日:1992-12-12
发明人: Mehta, Bharat
CPC分类号: A61F2/82 , A61B17/12022 , A61B17/12109 , A61B17/12118 , A61B17/12136 , A61F2/945 , A61F2/958 , A61F2002/30583 , A61F2002/823 , A61F2210/0085 , A61L31/048 , A61L31/145 , Y10S623/921 , C08L29/04
-
公开(公告)号:EP0547530A1
公开(公告)日:1993-06-23
申请号:EP92121203.1
申请日:1992-12-12
发明人: Mehta, Bharat
CPC分类号: A61F2/82 , A61B17/12022 , A61B17/12109 , A61B17/12118 , A61B17/12136 , A61F2/945 , A61F2/958 , A61F2002/30583 , A61F2002/823 , A61F2210/0085 , A61L31/048 , A61L31/145 , Y10S623/921 , C08L29/04
摘要: A vascular structure (24), including an artery, vein or vessel, with a peripheral wall (40) defining a cavity (32) and having a localized abnormal wall (20) is treated by inserting a device (44) of a hydrogel material into the cavity (32); and then hydrating and expanding the hydrogel material until the device (44) occludes the localized abnormal wall (20), sealing it from the cavity (32) of the vascular structure (24). For delivery and placement of the hydrogel implant (44) a catheter (80) is provided comprising an expandable balloon (84) affixed to the distal end of the catheter (80).
摘要翻译: 包括具有限定空腔(32)并具有局部异常壁(20)的周壁(40)的血管结构(24)包括动脉,静脉或血管,通过插入水凝胶材料的装置(44) 进入空腔(32); 然后水合和膨胀水凝胶材料,直到装置(44)封闭局部异常壁(20),将其与血管结构(24)的空腔(32)密封。 为了输送和放置水凝胶植入物(44),提供导管(80),其包括固定到导管(80)的远端的可膨胀气囊(84)。
-
公开(公告)号:EP0470494A1
公开(公告)日:1992-02-12
申请号:EP91112857.7
申请日:1991-07-31
CPC分类号: G01N33/86 , C12Q1/56 , G01N2333/968 , G01N2333/972
摘要: A plasminogen, which has a label incorporated into an active site thereof such that said plasminogen is enzymatically and catalytically inactive upon its conversion to plasmin, and an enzymatically and catalytically inactive plasmin with a label incorporated into an active site thereof.
A method of making a labelled plasminogen which is enzymatically and catalytically inactive upon conversion to plasmin comprising:
a) forming a streptokinase plasminogen complex,
b) inhibiting the plasminogen by attaching a peptide chloromethyl ketone thereto,
c) adding a detectable molecule or marker to the peptide group derived from said peptide chloromethyl ketone thereby forming a labelled complex, and
d) dissociating the streptokinase from the labelled plasminogen thereby forming a labelled plasminogen which is enzymatically and catalytically inactive upon conversion to plasmin.
Preferably, the peptide chloromethyl ketone is [-(acetylthio)acetyl]-phenylalanine, phenylalanine, arginine, chloromethyl ketone and the detectable molecule or marker is a fluorophore acetamide attached to the thiol group thereof.摘要翻译: 一种纤溶酶原,其具有掺入其活性位点的标记,使得所述纤溶酶原在其转化为纤溶酶时是酶促和催化失活的,以及具有并入其活性位点的标记的酶和催化无活性纤溶酶。 一种制备标记的纤溶酶原的方法,其在转化为纤溶酶时是酶促和催化失活的,其包括:a)形成链激酶纤溶酶原复合物,b)通过将肽氯甲基酮连接到其上来抑制纤溶酶原,c)将可检测的分子或标记物加入到 衍生自所述肽氯甲基酮的肽基团,从而形成标记的复合物,和d)从标记的纤溶酶原解离链激酶,从而形成标记的纤溶酶原,其在转化为纤溶酶时是酶促和催化失活的。 优选地,肽氯甲基酮是[(乙酰硫基)乙酰基] - 苯丙氨酸,苯丙氨酸,精氨酸,氯甲基酮,可检测分子或标记是连接到其硫醇基上的荧光团乙酰胺。 使用在转化为纤溶酶时在酶促和催化失活的标记的纤溶酶原的测定方法包括:a)将纤溶酶原加入到样品中,和b)通过观察提供的可检测的变化来监测纤溶酶原转化为酶促和催化无活性的纤溶酶 通过标记表示催化所述转化的组分的存在。 Ë
-
-